Nadia Stefanova Selected Research

Multiple System Atrophy

2/2022	Host oligodendrogliopathy and ɑ-synuclein strains dictate disease severity in multiple system atrophy.
1/2022	Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?
1/2022	The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy.
11/2021	ATH434 Reduces α-Synuclein-Related Neurodegeneration in a Murine Model of Multiple System Atrophy.
11/2021	Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy.
10/2021	Current experimental disease-modifying therapeutics for multiple system atrophy.
9/2021	Is Multiple System Atrophy a Prion-like Disorder?
1/2021	Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease.
1/2021	The Concept of α-Synuclein Strains and How Different Conformations May Explain Distinct Neurodegenerative Disorders.
1/2020	High-salt diet does not boost neuroinflammation and neurodegeneration in a model of α-synucleinopathy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nadia Stefanova Research Topics

Disease

55	Multiple System Atrophy 02/2022 - 08/2003
25	Parkinson Disease (Parkinson's Disease) 01/2022 - 08/2003
22	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2021 - 08/2003
19	Synucleinopathies 01/2022 - 09/2009
9	Parkinsonian Disorders (Parkinsonism) 01/2016 - 10/2004
7	Dementia (Dementias) 01/2021 - 06/2011
7	Striatonigral Degeneration 01/2019 - 08/2003
6	Cerebellar Ataxia (Dysmetria) 01/2016 - 03/2005
5	Neuroinflammatory Diseases 01/2022 - 11/2007
4	Disease Progression 11/2021 - 08/2014
4	Olivopontocerebellar Atrophies (Olivopontocerebellar Atrophy) 11/2021 - 03/2005
4	Gliosis 01/2020 - 09/2009
2	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 01/2013
1	Prion Diseases (Transmissible Spongiform Encephalopathies) 09/2021
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	Multiple Sclerosis 01/2020
1	Inflammation (Inflammations) 01/2020
1	Bone Fractures (Bone Fracture) 01/2020
1	Wounds and Injuries (Trauma) 01/2020
1	Proteostasis Deficiencies 01/2019
1	Demyelinating Diseases (Demyelinating Disease) 01/2018
1	Atrophy 01/2018
1	REM Sleep Behavior Disorder 11/2015
1	Spinal Cord Injuries (Spinal Cord Injury) 10/2015
1	Paraplegia (Spastic Paraplegia) 10/2015
1	Shock 10/2015
1	Spinal Cord Ischemia 10/2015
1	Ganglion Cysts (Ganglion) 08/2015
1	Human Influenza (Influenza) 05/2015
1	Seizures (Absence Seizure) 09/2011
1	Epilepsy (Aura) 09/2011
1	Shy-Drager Syndrome 08/2010
1	Glioma (Gliomas) 01/2008
1	Neoplasms (Cancer) 01/2008
1	Autonomic Nervous System Diseases (Dysautonomia) 03/2005
1	Huntington Disease (Huntington's Disease) 02/2005

Drug/Important Bio-Agent (IBA)

34	SynucleinsIBA 02/2022 - 02/2011
10	alpha-SynucleinIBA 01/2022 - 08/2003
8	Proteins (Proteins, Gene)FDA Link 02/2022 - 08/2003
7	Levodopa (L Dopa)FDA LinkGeneric 01/2019 - 10/2004
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2014
4	3-nitropropionic acidIBA 05/2012 - 08/2003
3	IronIBA 01/2022 - 01/2018
3	CytokinesIBA 01/2020 - 08/2003
3	3- (1,3- benzodioxol- 5- yl)- 5- (3- bromophenyl)- 1H- pyrazoleIBA 01/2020 - 01/2016
3	Neuroprotective AgentsIBA 09/2011 - 10/2004
2	PrionsIBA 01/2022 - 09/2021
2	ATH434IBA 01/2022 - 11/2021
2	Biological ProductsIBA 11/2021 - 01/2018
2	Toll-Like Receptor 4IBA 10/2021 - 01/2017
2	Amyloid (Amyloid Fibrils)IBA 01/2020 - 01/2013
2	Toll-Like Receptor 3IBA 01/2020 - 10/2015
2	AntibodiesIBA 01/2018 - 08/2015
2	Dopamine (Intropin)FDA LinkGeneric 12/2017 - 02/2005
2	Messenger RNA (mRNA)IBA 01/2016 - 01/2008
2	Toll-Like Receptors (Toll-Like Receptor)IBA 10/2015 - 08/2011
2	Peroxidase (Myeloperoxidase)IBA 10/2015 - 05/2012
2	Pharmaceutical PreparationsIBA 08/2014 - 12/2005
1	8-hydroxyquinazolin-4(3H)-oneIBA 01/2022
1	CopperIBA 11/2021
1	Chelating AgentsIBA 11/2021
1	ChemokinesIBA 01/2020
1	SaltsIBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Histone Deacetylase 6IBA 01/2020
1	Retinaldehyde (Retinal)IBA 01/2020
1	Macrophage Colony-Stimulating FactorIBA 01/2018
1	Isradipine (Dynacirc)FDA LinkGeneric 12/2017
1	monophosphoryl lipid AIBA 01/2017
1	MicroRNAs (MicroRNA)IBA 01/2016
1	HemocyaninsIBA 05/2015
1	L-type calcium channel alpha(1C)IBA 01/2013
1	Proteasome Endopeptidase Complex (Proteasome)IBA 07/2012
1	Oxidopamine (6 Hydroxydopamine)IBA 01/2012
1	Peptides (Polypeptides)IBA 09/2011
1	preproenkephalinIBA 09/2011
1	Erythropoietin FDA Link 02/2011
1	AcidsIBA 09/2009
1	rasagiline (Azilect)FDA Link 04/2008
1	Monoamine Oxidase (MAO)IBA 04/2008
1	ParaffinIBA 01/2008
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2008
1	LigandsIBA 01/2008
1	ElementsIBA 01/2008
1	Aspartic Acid (Aspartate)FDA Link 02/2005
1	Alanine (L-Alanine)FDA Link 02/2005
1	Caspase 3 (Caspase-3)IBA 02/2005
1	Valine (L-Valine)FDA Link 02/2005
1	acetyl-aspartyl-glutamyl-valyl-aspartalIBA 02/2005
1	CaspasesIBA 02/2005
1	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketoneIBA 02/2005
1	Quinolinic AcidIBA 02/2005
1	Minocycline (Cyclops)FDA LinkGeneric 10/2004
1	Green Fluorescent ProteinsIBA 08/2003

Therapy/Procedure

11	Therapeutics 01/2022 - 03/2005
3	Transplantation 09/2009 - 12/2005
1	Extracorporeal Shockwave Therapy 01/2020
1	Immunotherapy 01/2018
1	Endovascular Aneurysm Repair 10/2015
1	Immunomodulation 01/2011